2024-03-31-accounts

ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

CONTENTS

CONTENTS
Message from our CEO	3
About STOPAIDS	4
Our impact: Major highlights
April 2023 – March 2024	6
Advocacy impact area 1: People over profit	10
Advocacy impact area 2: Quality of life	14
Advocacy impact area 3: Transforming aid,
solidarity and development co-operation	18
Membership Engagement	20
Hosting and supporting networks to
improve collaboration and coordination	21
Looking forward: Our plans for 2024/25	22
Our staff	23
Structure, governance and management	24
Independent Auditor’s Report to the
members of STOPAIDS	28
Statement of Financial Activities
for the year ended 31 March 2024	31
Balance Sheet	32
Statement of Cash Flows	33
Notes to the accounts for the year
ended 31 March 2024	34

MESSAGE FROM OUR CEO

Over 2023-24 we entered the second year of our organisational strategy and the first full year of implementing our anti-oppression framework. We identified and implemented anti-oppression experiments across all of our work, internally and externally, and regularly monitored and shared reflections. With partners we identified many key opportunities in the UK and globally to try to address systemic change across our three advocacy impact areas, rebalancing power and funding towards low- and middle-income countries.

In the UK, we began to make some inroads into broadening sector engagement on the topic of anti-oppressive practice helping us to open discussions with civil society partners and funders and build stronger relationships. The sector as a whole continued to reflect and make gradual change towards decolonising international development and this was also reflected in the FCDO with the launch of the White Paper on International Development in November 2023 which made some important foundational, if not fully realised, steps in the right direction. The political environment in the UK continued to be challenging but it became clear towards the end of the year that a General Election was not far away and so eyes turned to influencing manifestos and potential new government priorities.

At the same time, at the global level there were multiple processes that attempted to identify, codify or implement needed steps towards an improved global health architecture and response. The Future of Global Health Initiative process ran its course throughout 2023 culminating in the Lusaka Agenda in December – a flawed but important process that provided a critical outlet for LMIC stakeholders to give voice to festering long-term concerns with global health architecture that were crystalised by the pandemic. Different fracture lines surfaced in the Pandemic Accord negotiations hosted by the WHO, with member states struggling to find much accord while navigating significant public suspicion. The summer also saw three high level meetings – on UHC, on PPPR and on TB – all of which struggled to set significant new commitments. The broader expansion of conflict in this year and the fracturing global order all made collective agreement even more challenging. Throughout all these processes, STOPAIDS has sought to ensure the voices of civil society and communities were meaningfully involved and the lessons of the HIV response and the priorities of the people living with and affected by HIV to the centre. This year also underlined the growing need for the HIV sector to chart its future towards 2030 before others did it for them and we engaged in and tried to prompt such discussions.

Internally we continued to make the changes needed to make STOPAIDS systems fit for a medium-sized organisation and for hosting smaller organisations or projects effectively. This year saw us face a challenging fundraising target and the need to start reflecting more deeply about how we articulate our impact in relation to our positionality and changing donor priorities. All in all, it feels that we are reading, navigating and even occasionally channelling shifting UK and global sands well and that is a huge testament to the amazing collaboration between staff, trustees, members and partners.

Mike Podmore Chief Executive Officer, STOPAIDS

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 3

ABOUT STOPAIDS

Our vision is a world without AIDS, where all people can realise their right to good health and wellbeing.

STOPAIDS is a UK-based HIV, health and human rights advocacy network made up of 70 organisations. We draw on our 35-year experience working on the HIV response to support UK and global movements that challenge the systemic barriers and inequalities that prevent people from realising their right to health and wellbeing.

OUR STRATEGY

We are now three years into our current four-year strategic plan (2022-2025). The strategy’s overarching goal is for STOPAIDS to secure key steps towards transforming funding, power and systems, particularly for people living with and affected by HIV and marginalised populations. It focuses on three advocacy impact areas:

People over profit

Ensuring enhanced quality of life for people living with and affected by HIV

Transforming aid, solidarity and development co-operation

Action in each area is delivered through five key strategic approaches (as outlined in the infographic below) and is grounded in our Anti-Oppression Framework.[1]

STOPAIDS’ ANTI-OPPRESSION FRAMEWORK

Our work is framed by our living anti-oppression framework aims to challenge and reverse problematic or oppressive logics and promote anti-oppressive values in our working practices.

The framework is grounded in four key values:

1. Humility: Ways of working that show self-restraint, but also ask you to reflect on your positionality, the power dynamics involved, and the value of / need for your contribution in an activity or setting.

1. Shifting power: Ways of working that not only seek to halt exploitative practices, but also address the cumulative disadvantages that exploitation has left behind by redistributing power.

2. Solidarity: Ways of working that ask you to take as many opportunities as possible to ‘spend’ your social capital or use your position / resources to challenge stigmas and the continued demonisation of certain people / groups.

3. Co-ownership: Ways of working that don’t presume the superiority of your approach and instead create opportunities to benefit from missing insights and skills by engaging in collective work.

This was the first year that the framework was fully implemented. In each impact area, we are trialling ways to turn these ideas into practices, helping to embed the framework’s values into our everyday work. Examples of some of these adaptations are reflected in the sections on our impact areas. By sharing our learnings and being visible about where things have gone to plan and where they haven’t, we hope to encourage a continued and evolving dialogue on how we live up to our anti-oppressive goals within our sector.

1. In 2023/24, a funding shortfall forced us to take the difficult decision to deprioritise the following strategic goals: Clear principles drive the private sector’s role in health to reduce inequality and deliver global health goals (Advocacy Impact Area 1); Sustained investments for the most marginalised in current aid eligibility, allocation and transition systems (Advocacy Impact Area 3). As a result, this annual review does not report on these areas.

4 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

----- Start of picture text -----
STRATEGY DIAGRAM
2022-2025
----- End of picture text -----

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 5

OUR IMPACT: MAJOR HIGHLIGHTS APRIL 2023 – MARCH 2024

Impact area 1: People over profit

A public-health driven model for researching and developing affordable, safe and effective health technologies for all

• We made progress towards influencing Labour’s 2024 Manifesto by co-developing manifesto briefs for Labour with the Missing Medicines Coalition. These included updated evidence from our Access Denied report series to make compelling arguments about why this Government should back our policy recommendations. These were tailored to be relevant to 3 Labour shadow briefs: international development, health and social care and, science, technology and innovation and were shared with the Special Advisors for each shadow brief. We were also able to use these reports to build more public awareness about the amount of tax-payer’s money that was spent on Covid-19 tools and the need for global equitable through 2 feature articles in The National and Yahoo ! News.

• In addition, we used the research in this report to make a submission to the Department for International Trade that relying on the good will of pharmaceutical companies to engage in voluntary licenses is too risky an option to deliver equitable access. Specifically, the research was helpful in informing our ask about mandating the sharing of pharmaceutical know-how and how this could work from a legal perspective.

• We also made progress on pushing for equity to be built into PPR approaches by building deeper relationships with civil servants working on the pandemic accord and increasing parliamentary awareness. We did this by

hosting a parliamentary event on COVID-19 and future pandemic preparedness which was well attended. With members of the Missing Medicines coalition and other partners we also met with the FCDO and DHSC teams who are involved in the Pandemic Accord Negotiations and highlighted the need for conditionality attached to public funding to ensure affordability and technology transfer as part of the Pandemic Accord to them. We also increased public awareness of the Pandemic Treaty by producing a video with a patient leader and Baroness Shami Chakrabarti for social media that highlighted the lessons learned and the need for the UK Government to support equitable access in the Pandemic Treaty.

• STOPAIDS and the Missing Medicines Coalition in 2023 increased our pressure on decision makers to prevent the introduction of text within the UK-India FTA that would lead to increased medicine pricing globally and weaken India’s generic pharmaceutical industry. We supported MSF AC with a letter they drafted to then PM Rishi Sunak which used the success of the patent opposition in India to TB drug Bedaquiline as a key example of what is at stake if the UK pushed for harsher IP laws within the FTA text. With the change of government in the UK and other world events, the signing of the FTA has been delayed which gives us a greater window of opportunity to continue to influence the negotiating team. We ensured our letter to Rishi Sunak was informed by civil society based in India working on the UK-India FTA by connecting with KM Gopakumar from Third World Network who reviewed and signed off on the messaging in the letter.

6 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

Digital Health and Rights Project meeting in Kenya.

Digital health technology and human rights

• In 2023 we completed our second grant from Botnar Foundation, building on previous work to support the UNSR on the right to health to develop her report on digital health, and hosting three workshops to empower youth and civil society to use the report findings. We also began work on a subsequent grant from Botnar Foundation including recruiting an Advocacy Manager, and leading the development of the Digital Health and Rights Project’s advocacy strategy and anti-oppression workstream.

• Our work on reducing ‘digital divides’ and toward improved digital empowerment has continued, with the development of a ‘Digital Literacy 101’ Toolkit with GNP+ and the Engine Room and dissemination of the toolkit during a three-part youth training series. In 2024, STOPAIDS’ CEO began a visiting fellowship at the University of Warwick, building on this work with research on the investment of overseas development assistant donors in digital literacy and empowerment.

• We have supported young people and marginalised groups to be meaningfully involved in the governance of digital technologies, engaging approximately 170 young people in events and training workshops to build their advocacy capacity and supporting the inclusion of young people at high-level events including the UN General Assembly and World Health Summit.

• Finally, our digital rights advocacy has strengthened policy mechanisms for digital governance. For instance, our work with the UNSR resulted in inclusion of our recommendations in her report on digital health and rights and the OHCHR acknowledged content in our submission to the General Recommendation N° 37 on racial discrimination. We’ve built a strong relationship with the WHO Department of Digital Health with outcomes including a commitment to increasing youth participation in their work. Finally, following our advocacy, the Global Fund included a reference to the impacts of online abuse and harassment towards marginalised communities in their 2023-2025 Advocacy Roadmap.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 7

Impact area 2: Ensuring enhanced quality of life for people living with and affected by HIV

• We continued to support the Global Fund replenishment campaign building and mobilising parliamentary and public support for the global fund, including running an event at the Labour Party Conference. One key advancement was our successful organisation of an all-day strategy meeting for the Global Fund - Gavi Coalition, leading to the agreement on a new theory of change, organisational structure, and collaborative ways of working. The meeting also facilitated a productive engagement between the coalition and the joint FCDO Immunisation and Health teams, which was positively received by FCDO. The approach was recognised for aligning with FCDO’s strategy on replenishments.

• We held a World AIDS Day Conference which provided a significant platform to highlight the importance of Unitaid’s work and how its working to ensure more meaningful engagement with communities in front of civil society (including communities), MPs and FCDO. We also developed a social media toolkit which we shared on World AIDS Day which showcased Unitaid’s impact and the continued need for a fully funded response. Additionally, we coordinated two parliamentary events that helped situate Unitaid’s work

within UK global health priorities: 1) ending preventable deaths of women and girls and 2) building global partnerships with UK scientists. Ahead of International Women’s Day, we hosted a parliamentary roundtable alongside the Global Health APPG, the APPG on HIV and AIDS and the Malaria and NTDs APPG entitled ‘Saving Lives Faster: Ending Preventable Deaths of Women by 2030’; and during British Science Week, we held a reception entitled ‘British health R&D: Innovation that delivers global impact to reach the SDGs by 2030’.

• We also focused our efforts on The Robert Carr Fund (RCF) Replenishment. At our World AIDS Day Conference, the Senior Responsible Owner (SRO) for The Robert Carr Fund (RCF) Replenishment at FCDO spoke on our panel on ‘Punitive Laws’ and said that the UK remains committed to RCF. We also actively collaborated with other organisations such as GNP+ to develop a unified and diverse advocacy strategy for the replenishment of RCF. In January 2024, we developed a work plan for the replenishment of RCF, aiming to secure a substantial pledge and continuous support from the UK Government while also enhancing CSO and public awareness regarding the RCF.

UNAIDS Communities Lead event at STOPAIDS World AIDS Day Conference, December 2023.

8 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

Impact area 3: Transforming aid, solidarity and development co–operation

• STOPAIDS is a founding member of the Global Public Investment Network and co-created and co-lead the global health sub-working group with ITPC. Through this mechanism we advanced discussions around the GPI concept of ‘all decide’, and our article in the GPIN report “Time for Global Public Investment” was launched at the UN General Assembly.

• We advocated for the meaningful involvement of communities and civil society including in the Pandemic Accord negotiations and mobilised civil society to demand stronger participation in the negotiations through letters and meetings with Member States. This resulted in civil society stakeholders being invited to attend two meetings with Member States in March 2024; this work will continue to improve participation and to ensure the future governance structure of the Accord is inclusive.

• We supported civil society and community engagement in pandemic preparedness processes by coordinating a series of FCDO/ DHSC meetings on the Pandemic Accord with civil society on behalf of Action for Global Health. With limited participation in the negotiation process, these meetings have been a key space to discuss civil society priorities. We have also provided information on the Pandemic Prevention, Preparedness and Response High-level Meeting to support civil society to engage in the process through regional consultations and community-led webinars and worked with partners to develop key asks. In addition, we have supported civil society representatives in the Lusaka Agenda working group.

• Through our role in the Developed Country NGO Delegation to the Global Fund we have supported the recruitment of the Board Member and development of the delegation retreat agenda. We have led the launch of a research consultancy on the digital rights challenges that civil society implementers face and recommendations for the Global Fund. We have also enabled strong collaboration, intel-sharing and alignment in messaging between the delegation and civil society involved in the Lusaka Agenda/ Future of Global Health Initiative by delivering presentations to the delegation.

STOPAIDS CEO Mike Podmore, Solange Baptiste and colleagues at UNGA 2023.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 9

ADVOCACY IMPACT AREA 1: People over profit

People must be put before profit. This is the only way to ensure every person can claim their right to good health and wellbeing, including marginalised populations. That’s why a huge focus of our advocacy efforts is on securing equal access to medicines, realising people’s digital health rights, and defining the private sector’s role in global health.

Public health-driven health innovation systems, and equitable and urgent access to safe, effective and affordable health technologies for all

This year, we continued to advocate for improved access to medicines and campaign against the extreme profiteering of the pharmaceutical industry.

We continued to negotiate an extension of the June 2022 TRIPS waiver for COVID-19 vaccines, despite efforts stalling on the US side, and continued to build relationships with civil servants in the UK Department for International Trade (DIT) to further influence the UK’s position. After submitting evidence to the government’s White Paper on international development, we were encouraged to see that the final paper, published in November 2023, included some progressive language on access to medicines and knowledge sharing and stated that low- and middle-income countries must be equal partners in the future of health science and research. Mindful of the US’ influence on the then UK government, we sought to mobilise influence by attending the US government’s TRIPS waiver extension evidence hearing, which ensured that half of the hearing’s participants represented civil society. We also used an event at the London School of Economics to engage Ngozi Okonjo-Iweala, Director-General of the World Trade Organization, on the issue, asking multiple questions on the state of the TRIPS waiver and intellectual property for equitable access to medicines.

We further built our relationship with the Medicines Patent Pool, which in early 2023 was seeking financial and technical support from the UK government for the World Health Organization’s (WHO) mRNA Technology Transfer Hubs. The hubs aim to build the capacity of low- and middle-income countries to produce mRNA vaccines, and as such have the potential to significantly advance equal access to medicines.

We mobilised the Missing Medicines Coalition and People’s Vaccine Alliance, and together we developed a range of actions designed to influence the UK government on the mRNA hubs, including an impactful parliamentary event where participants were briefed on issue and given the opportunity to ‘experience’ the hubs via virtual reality headsets. STOPAIDS also organised a panel on how learnings from the HIV response can be used to inform pandemic preparedness and response (PPR) work, attended by UK government representatives and parliamentarians, and used the opportunity to raise awareness about the hubs and how vital UK support is for the initiative.

We continued to advocate for public-health driven medical research and development, publishing our final Access Denied Report which explores the role UK public entities have played in supporting the development of COVID-19 tools such as diagnostics, vaccines and treatments. The National and Yahoo ! News featured the report, and we will continue to use interest in the report and the rest of the Access Denied series to push the new government and influencing opposition parties for fairer medical research and development and a fairer pharmaceutical system.

10 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

We made progress on the issue of pharmaceutical licences, submitting evidence to the UK’s non-paper on Technology Transfer and Voluntary Licenses, via DTI. We used this opportunity to reiterate why relying on the good will of pharmaceutical companies to engage in voluntary licenses is too risky an option to deliver equitable access. Using the evidence gathered through our Access Denied research, we presented findings on the importance of having the option to mandate pharmaceutical companies to share knowledge, and how this could work from a legal perspective.

STOPAIDS was asked to coordinate a letter to Gilead urging them to share the licenses for long-acting HIV treatment Lencapavir with the Medicines Patent Pool. Aware that there is some push-back to licencing medicines through the Medicines Patent Pool due to the geographic restrictions which are often put on the licenses, before acting we consulted Afro-CAB, which advised us to wait until it has engaged in direct engagement with Gilead on the issue. In this way, we acted with humility, consulting those who were best placed to make the decision on whether the pool is the best route for global access to Lencapavir and taking our lead from them.

Other key work around advocating for equal and urgent access to HIV and COVID-19 health tools has been delivered through our coordination of the Missing Medicines Coalition. This year, STOPAIDS and the Missing Medicines Coalition continued to work to prevent the introduction of text within the UK-India Free Trade Agreement which would lead to increased medicine pricing globally and weaken India’s generic pharmaceutical industry. To influence UK decision-makers, we coordinated a letter from civil society organisations in low- and middle-income countries to the International Trade Secretary, which gained significant media coverage in Politico, The Telegraph, GB News other outlets, and worked with other coalition members to on separate media coverage from Devex and Bloomberg.We contributed support to a letter from Médecins Sans Frontières to the then Prime Minister Rishi Sunak, which used the success of the patent opposition in India to TB drug Bedaquiline as a key example of what is at stake if the UK push for harsher IP laws within the FTA text. To ensure this action was

truly reflective of community needs, we reached out to patient organisations and others within India civil society who are involved in advocacy around the agreement, ensuring they had ample opportunity to review the letter. Due to the conflict in Gaza and the change of government following the 2024 UK elections, the signing of the FTA has been further delayed. We will continue to use this window of opportunity to convene our members and key partners and mobilise the media and political players to further influence the negotiating team.

In the run up to the UK election, we partnered with Global Justice Now to develop tailored party briefings on how to achieve global equitable access to medicines, both to shape manifestos and inform future policies, which were then endorsed by Just Treatment, UAEM and Oxfam. STOPAIDS CEO Mike Podmore met with Lisa Nandy’s special advisor when Nandy was Shadow International Development Minister to brief them on this issue, as well as sending the briefings to leading figures within the Conservative and Liberal Democrat parties on issues relating to science, innovation and technology. We also contributed to BOND’s sector-wide manifesto writing process. As part of our anti-oppression work, we shifted our focus in relation to influencing foreign policy from ending global poverty to ending global inequality, placing greater emphasis on the need to address the root causes of poverty and systemic issues related to inequality.

Meaningful civil society involvement in design, implementation and governance of digital technologies and AI in health

The economic, social and racial inequalities that exist in the real world are just as present in the digital one. Millions of people are still offline. Women and girls, as well as those living in rural areas, on low incomes and with less education, are particularly affected – and this is causing many people to miss out on the health services they need. Those who are online are being exposed to privacy leaks, poorly managed health data and the denial of information and services due to algorithmic bias. People living with or affected by HIV are especially at risk of harm and discrimination.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 11

We are on a mission to end this. We want a world in which there is a progressive and rights-based approach to digital technologies and artificial intelligence (AI) in health. This year, to further our work in this area, we continued to analyse and advocate for strengthened digital rights protections in the high-level meetings on universal health care (UHC), pandemic preparedness, prevention and response (PPPR) and tuberculosis (TB).

I want to thank you for providing me with the opportunity to take part in the digital health rights training. I learned so much from the course and feel more confident in my ability to advocate for digital health rights …I hope to continue to learn and grow as an advocate in the future.

A young person who participated in STOPAIDS’ youth training on advocacy for digital health and rights

We widely disseminated our digital rights briefing for UHC, adding additional analysis of the first drafts of the related Political declarations through a STOPAIDS-led statement. While the UHC declaration had not strengthened human rights language on digital health specifically, language referencing the digital divides and the need to protect data and privacy was retained. At the United Nations General Assembly, we were able to further raise awareness about the issue, disseminating briefings on digital health at the UN High-Level Meetings, and attending events relevant to digital health such as a Transform Health Coalition event. We also supported digital health to be profiled by a DHRP panellist at a side event on governance, co-hosted by STOPAIDS, which was well-attended by government and multilateral representatives.

We continued to raise awareness about digital rights among the Global Fund Board, spotlighting the issue with five country constituencies and technical partners through the Developed Country NGO delegation’s bilateral meetings. There had been little further opportunity for the Board to discuss human rights as part of the Global Fund’s Digital Framework, so to push things along we met with the Global Fund’s HIV technical advisor to better understand opportunities for influence.

It is essential that young people, communities and civil society are empowered to understand and have a say in policymaking that affects their digital rights. We also need global health agencies and decision-makers to put people at the centre of digital approaches. That’s why we are working to increase mobilisation amongst civil society and communities (including young people) on digital health and rights, and have made significant strides on this area this year.

We continue to make a significant contribution to the Digital Health and Rights Project (DHRP) Consortium, playing an important role in DHRP’s Steering Committee, managing advocacy across the consortium, and supporting outreach for the project. This year, we supported preparations for a new threeyear DHRP participatory action research project, including a successful inception week in Kenya. STOPAIDS hosted sessions on advocacy and anti-oppression during the week, facilitating interactive mapping exercises which have subsequently shaped both the advocacy and research strategies. Since this meeting, we have continued to lead the Consortium’s advocacy strategy development, facilitating multiple mechanisms for feedback and input from partners, including through consultation sessions, a group brainstorming call, and written feedback opportunities.

As part of our project engaging with the UN Special Rapporteur on the Right to Health, we held a joint DHRP event on the sidelines of the Human Rights Council. A range of speakers across the UN and civil society allowed for an in-depth discussion with around 160 in-person and virtual participants, including several key targets from the IT, Strategy and CRG teams at the Global Fund. In another key global forum – the World Health Summit in October 2023 – we disseminated briefings on the work of DHRP, raised key questions at high-level events and met with key stakeholders including DTH-Lab, Tactical Tech, and STOPAIDS members such as Mothers2Mothers. A particular success was engaging with the Director of Digital Health at WHO, who agreed to follow-up meetings with a focus on youth-engagement. We were also able to build on our relationship with Fondation Botnar, the DHRP Project funder, meeting with them in-person and co-authoring an article in the official Summit handbook.

12 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

STOPAIDS Staff at World Health Summit, Berlin, 2023.

STOPAIDS was also represented at RightsCon in Costa Rica, networking with digital rights civil society, youth networks and donors. At the event, we facilitated a virtual panel alongside GNP+, with speakers including Neema Lugangira MP (from Tanzania) and a representative from the OHCHR B-Tech project, who shared valuable perspectives on the role the UN, governments and young people can play to push social media companies to protect young people’s digital health and rights.

iT4 The depth of insight and expertise presented throughout the series has been immensely valuable and is appreciated. I look forward to continued engagement with your work and eagerly anticipate future contributions from your team.

A young person who participated in STOPAIDS’ youth training on advocacy for digital health and rights

We have also increased young people’s knowledge and skills on digital rights and advocacy, which is essential for driving change in this area. During Transform Health’s Digital Health Week, we launched a Digital Literacy Toolkit, created in partnership with GNP+ and YET4H, and hosted a workshop for young people to elicit feedback on the UN Special Rapporteur’s report on digital health and rights.

With funding from our Botnar grant, we hosted a three-part youth training series on advocacy for digital health and rights attended by around 50 young people. Before and after surveys demonstrated the impact on young people’s digital literacy, for instance, there was a 45% increase in participants’ understanding of digital health. The training series enable us to strengthen our relationship with youth networks, including Students for Global Health, and to develop our own network with 25 young people registering for future communications.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 13

ADVOCACY IMPACT AREA 2: Quality of life

Quality of life is a broad-ranging concept, which can include a person’s physical health, mental state, economic opportunities, personal beliefs and relationships. Societal wellbeing (for the most part influenced by government choices in areas including education and health) can play an important part in determining someone’s overall quality of life. We are working to ensure quality of life is an essential component of everyday life and not an optional extra. In this area of our work, we undertake strategic advocacy to ensure that the HIV response is not simply about prolonging the lives of people living with and most affected by HIV, but supporting people to be healthy, happy and fulfilled.

We are doing this by advocating for funding to ensure quality HIV services and community responses, by integrating HIV and rights into broader health services, and by addressing barriers that prevent us from ending AIDS, like criminalisation and gender inequality.

Enhanced funding for and access to quality HIV prevention, treatment, care and support

We were front and centre in key discussions and processes relating to funding replenishments from the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Robert Carr Fund (RCF).

In April, the STOPAIDS CEO and Senior Campaigns and Media Advisor both attended the Global Fund Advocates Network Annual Meeting, which enabled us to strengthen relationships with global advocates, explore future collaborations and strategise for the eighth replenishment campaign. This year, STOPAIDS’ CEO stood down from GFAN’s International Steering Committee, while our Senior Campaigns and Media Advisor joined it. By continuing our presence on the committee, STOPAIDS can continue to influence GFAN’s strategic direction.

At the Annual GFAN meeting we co-hosted a workshop with WACI Health and GFAN Asia-Pacific designed to achieve better and more equitable collaboration between advocates from countries with different income statuses. Twenty-eight participants attended the workshop, and findings were then circulated to the wider STOPAIDS network for input before being presented to the UK Global Fund-Gavi Coalition to adopt as actionable steps.

In May 2023 the UK Civil society Working Group for Global Fund Replenishment held a strategy meeting to discuss this feedback from the Global Fund Advocates Network (GFAN) meeting and to evaluate our work on the previous replenishment campaign. STOPAIDS updated its Theory of Change for NVF Phase IV grant application and commissioned The Advocacy Team to complete an external evaluation of STOPAIDS and the Working Group’s replenishment campaign.

To expand the membership of the UK Civil society Working Group for Global Fund Replenishment, the STOPAIDS also met with The Borgen Project, which then joined the coalition, meaning there are now over 100 new campaigners in the UK working on the next Global Fund replenishment campaign.

We met with the FCDO in July to discuss plans and priorities for the high-level meetings, the International Development White Paper, and the Future of Global Health Initiatives report. STOPAIDS also led on the development of a key recommendations document for the then-new Shadow Minister for International Development.

We also influenced discussions at the Global Fund Board, through our role on the Developed Country NGO delegation, to ensure effective use of the remaining Covid-19 Response Mechanism funds, which total over US$1billion. We also monitored the relationship of the Global Fund with the Pandemic Fund and advocated for better alignment of Pandemic Fund and Global Fund processes, which would increase efficiencies and limit burden on countries.

14 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

The replenishment of the Robert Carr Fund is due to take place in August 2024. This year, in the run up to this crucial date, STOPAIDS began formulating a new advocacy strategy to secure the replenishment of the fund, working with GNP+ and the fund itself to explore collaborative opportunities and opportunities to develop partnerships with other global organisations to ensure a unified and diverse approach to the replenishment, as well as establishing a pledge target for the new UK government. We determined that the time was right to call for a significant increase in funding from the UK government from £7 million at the last replenishment to £10 million – a 43% increase – that would deliver the priorities for direct funding to vulnerable communities outlined in the new International Development White paper and supported by the likely incoming Labour Government. Youth STOPAIDS (hosted by STOPAIDS) plays a key role in our advocacy work around the Robert Carr Fund and it developed a digital campaign calling for the UK government to increase its pledge to the fund. The campaign hit its height with a speaker tour across the UK, which platformed the voices of young people living with and affected by HIV, inspiring youth-led action and advocating for increased funding in the lead up to the replenishment.

Another key global health insititution is Unitaid, which is instrumental in supporting innovation in global health and overcoming access barriers to medicines and diagnostics. This year, our collaboration with Unitaid continued as we were successful in winning additional funding from the organisation to continue UK work on Unitaid resource mobilisation, work which ran from September 2023 to March 2024. As part of this work, STOPAIDS successfully established the Unitaid Working Group to strategise on how to best raise Unitaid’s visibility within the UK.

STOPAIDS staff at STOPAIDS World AIDS Day Conference, December 2023.

Unitaid Deputy ED Tenu Avafia speaks at Parliamentary event hosted by STOPAIDS, February 2024

Rounding off 2023, the World AIDS Day Conference provided another important opportunity to showcase Unitaid’s efforts to ensure more meaningful engagement of communities to MPs, the FCDO and civil society. The conference’s focus on communities and community leadership ensured a stronger focus on the role of communities in Unitaid’s intervention. This provided an important opportunity for Unitaid senior leadership to hear from an array of community voices and gain deeper understanding of the value of community organisations. This will hopefully contribute to influencing the way Unitaid works with communities in the future and how it funds community organisations through it call for proposals.

On World AIDS Day 2023, STOPAIDS also shared graphics across its digital platforms highlighting Unitaid’s impact and the need for a fully funded response, which were later used in a social media toolkit that was shared with the Unitaid working Group.

Into 2024, we coordinated two parliamentary events which helped to situate Unitaid’s work within UK global health priorities. In February 2024, ahead of International Women’s Day, we co-hosted a parliamentary roundtable on ending preventable deaths among women and girls, alongside the Global Health APPG, the APPG on HIV and AIDS and the Malaria and NTDs APPG. Baroness Barker chaired the event with interventions from Theo Clarke MP, Patrick Grady MP, Lord Browne and community speakers who shared their lived experience and the difference Unitaid innovations had made to their lives. The roundtable was a critical opportunity to hear from Unitaid, parliamentarians, researchers, civil society,

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 15

and community speakers on efforts aimed at ending preventable deaths for women and children, with specific emphasis on maternal and reproductive health. Following the event, we coordinated meetings for Unitaid with various APPG Chairs to allow for further in-depth discussion on Unitaid’s value.

It was such a pleasure to see you all in London last week…I have taken careful note of all points of follow-up and are working through these…we were struck by the quality of the organisation and exposure you were able to facilitate.

Director of Strategy, Unitaid, reflecting on STOPAIDS and partners’ ending preventable deaths among women and girls roundtable

During British Science Week, we held a reception with the Life Sciences APPG, the Parliamentary and Scientific Committee and the APPG on HIV and AIDS, which connected UK research institutions and their work with Unitaid while allowing parliamentarians to gain greater visibility and understanding of the catalytic impact of the UK’s current investments to Unitaid.

Meaningful integration of HIV with broader physical and mental health issues and universal health care

There is a need for integrated, person-centred and community-led interventions that optimise the health and wellbeing of people living with HIV globally.

To drive progress in this area, we endeavoured to ensure key HIV issues and learnings were included in the discussions and declarations of the year’s three high-level meetings (HLMs): on universal health care (UHC), pandemic prevention, preparedness and response (PPPR) and TB. Given the number of HLMs that occurred in 2023 and their cross-cutting importance for STOPAIDS advocacy priorities, STOPAIDS developed an advocacy plan for the HLMs to coordinate internal engagement.

Working with other community and civil society partners, we produced a series of thematic policy briefs which explore common intersecting challenges across the HLMs (between HIV, TB, PPPR and UHC, digital Rights, global health

architecture and governance, anti-oppression and health equality, a person-centred approach and integrated care).

STOPAIDS convened a task team with GNP+, AVAC, Aidsfonds, Friends of the Global Fight US, WACI Health, Save the Children and Frontline AIDS to develop a civil society and communities statement of the Pandemic Prevention, Preparedness and Response which was published ahead of the multi-stakeholder hearings in May 2023. The aim of the statement was to ensure the zero draft of the political declaration was informed by the key principles of equity, inclusivity, and human rights for all with a set of action-oriented policy recommendations, building on the lessons learned from HIV, TB, malaria and COVID-19 responses. The statement was developed alongside a UHC statement convened by Aidsfonds to ensure similar language on our key recommendations, drawing on previously agreed text in political declarations. STOPAIDS also joined the UHC task team and provided input into several recommendations, particularly on human rights and digital health. To further the integration of mental health support into HIV services, we also contributed to the development of United for Global Mental Health’s key requests, in particular the importance of reforming punitive laws that lead to health inequalities.

Upon the release of the final political UHC declaration, STOPAIDS conducted a thorough analysis, comparing the 2023 declaration to the 2019 counterpart. Our focus was on aspects related to HIV, human rights language and community engagement. We compiled our findings in a comparative statement, which garnered endorsement from numerous global civil society organisations and was shared with the FCDO and broader civil societies during the UN General Assembly (UNGA).

At UNGA itself, as part of the Love Alliance partnership we co-hosted and our CEO spoke at a successful side event to highlight lessons learned from the HIV response to achieve inclusive governance, and the importance of funding. The Netherlands and South Africa are key governments involved in PPPR governance (including the Pandemic Accord and proposed medical countermeasures platform), and this event provided an important opportunity to promote our inclusive governance principles with decision-makers, ahead of the launch in October 2023 (see Advocacy impact area three below).

16 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

STOPAIDS engaged in multiple actions to show global solidarity with LGBTQ+ Ugandans and to attempt to stop the bill from passing, joining a Ugandan civil society organisations on global coordination calls to organise a Global Day of Action against the bill. We also led a UK solidarity demonstration outside the Ugandan High Commission, coordinated with UK Alliance for Global Equality. Participants included queer Ugandan speakers, LGBTQ+ speakers from UK Black Pride and Out & Proud African LGBTQI, and asylum groups. STOPAIDS also engaged the UK media on the issue, gaining coverage in Pink News, Gay Times, Openly News and other outlets.

The UN Summit, and related Pact of the Future, is a key moment and document for re-energising and re-shaping multilateralism and cooperation for achieving the SDGs and beyond, which provide important opportunities for integrating HIV into related fields.

This year, STOPAIDS was heavily involved in the Future of Global Health Initiatives Process, co-leading civil society involvement, convening civil society consultations and influencing the process and the final recommendations of the outcome document ( the Lusaka Agenda ), which was published in December 2023. In January 2024, a transitional working group was set up to ensure the recommendations of the Lusaka Agenda are picked up in each of the global health institution Boards. We continue to work with other global civil society partners and convene the civil society delegations to track the Lusaka Agenda processes.

Reduction of HIV-related structural barriers

Structural-related barriers, such as criminalisation and gender inequality, stop people getting tested for HIV, using HIV prevention tools like condoms and PrEP, and getting HIV treatment if they need it. That’s why it is critical that we also advocate for the removal of structural barriers that drive HIV related stigma and discrimination and derail efforts to end AIDS.

This year, Ugandan parliament passed the Anti-Homosexuality Bill, which includes the death penalty, life and other long prison sentences for homosexuality and failure to report homosexuality, making the rights situation even more dire for LGBTQI+ people in Uganda and sending an emboldening message to other homophobic regimes.

We briefed UK parliamentarians on the impact of the bill and civil society requests of government in response, sharing a briefing for a meeting with the APPG on HIV/AIDS and the APPG on LGBTQ+ Rights, and directly raised our concerns about the bill to the Ugandan Health Minister following an APPG event in Parliament.

In February 2024, our CEO joined other UKAGE CEOs for a face-to-face meeting with Minister Mitchell and Lord Herbert to advocate for a stronger UK response to the Uganda anti-homosexuality law. Shortly after this, the UK placed sanctions on several Ugandan politicians. In April, STOPAIDS also partnered with Dumi Gatsha to host a side-discussion at the annual GFAN meeting on LGBT+ rights and the global rollback of freedoms. In June 2023, we attended a Pride Month parliamentary reception hosted by the APPG on Global LGBT+ Rights, having supported an LGBT+ Ugandan asylum seeker to be a featured speaker. Lord Cashman also referenced the remarks from the reception in a speech during the debate on the Illegal Immigration Bill.

Our Ugandan allies tell us that now is the time for urgent action from the international community, as the Ugandan President gauges what the international community can tolerate on this issue. STOPAIDS has since released a public statement in response to the constitutional court ruling in Uganda to draw further attention to this issue, and we will continue to raise the issue with the new UK government.

Our work on gender included supporting the Global Fund Developed Country NGO Delegation to monitor work on Community, Rights and Gender (CRG). Throughout the year, STOPAIDS’ Advocacy Director led the sub-working group on CRG, and in doing so supported the delegation to analyse and develop a joint position on current governance discussions on the issue.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 17

ADVOCACY IMPACT AREA 3: Transforming aid, solidarity and development co-operation

Through our work we seek to transform aid, solidarity and development co-operation. This means moving away from the outdated structures and practices of international aid that concentrate power in the hands of the few, toward an approach that is built on meaningful involvement of all stakeholders, particularly people living with and most affected by HIV.

Meaningful civil society and community involvement in global health governance and pandemic preparedness and response

Between 2020 and 2023, WACI Health, GFAN and STOPAIDS established and hosted the Platform for ACT-A Civil Society and Community Representatives. The Platform provided systematic representation of civil society and communities across all pillars and working groups of the Access to COVID-19 Tools Accelerator (ACT-A), increased the ACT-A’s accountability and effectiveness and provided a model for ensuring strong standards of meaningful involvement of civil society and communities in global health initiatives. ACT-A came to an end in March 2023 and the Platform for ACT-A Civil Society and Community Representatives concluded its work.

Civil society and community partners attribute our work to improved representation in global governance spaces and in April 2023, WACI Health, GFAN and STOPAIDS collaborated with the Global Network of People Living with HIV (GNP+) to establish the Inclusive Global Health Institutions Project in April 2023 to continue this work. The Project focuses on increasing, and supporting, the meaningful participation of civil society and communities in decision-making and governance structures across global health governance and pandemic preparedness and response.

In October 2023, we launched the Principles of Meaningful Involvement of Communities and Civil Society in Global Health Governance alongside community and civil society delegations to

global health institutions. The principles were co-developed with representatives from the delegations and are a best practice guide for all stakeholders in global health. The principles aim to ensure the expertise and lived experience of communities and civil society is recognised and respected and that their voices and power in decision making processes is formalised to ensure more effective and representative governance structures.

By advocating for these principles which emphasise inclusivity and sustainability in international development, STOPAIDS is working to address structural and systemic forms of oppression within the development sector. Our leadership on inclusive governance is our main contribution to the Global Public Investment (GPI) concept of ‘all decide” and our article on this concept was published in Global Public Investment Network’s report, Time for GPI. Our CEO is also a member of the Global Public Investment Network Steering Committee and co-hosts its Global Health Working Group.

The COVID-19 pandemic has shown that, as a global community, we need to strengthen systems to prevent, prepare for and respond to public health emergencies. To drive action on this crucial issue, STOPAIDS has actively engaged in the drafting and negotiation of the Pandemic Prevention, Preparedness and Response (PPPR) Political Declaration. Throughout the year, STOPAIDS continued to play a key role in mobilising civil society to demand stronger community and civil society participation in the Pandemic Accord negotiations and future governance structure, and to ensure that key stakeholders, including the WHO and UK government, understand civil society concerns.

18 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

Achieving Inclusive Governance event UNGA, September 2023.

We published Pandemics start and end in communities: Why civil society participation in the governance of the Pandemic Accord is critical with Save the Children, providing WHO and Member States with a blueprint for engaging civil society in negotiating, governing, monitoring and overseeing international instruments. We further advanced this work as an official stakeholder of the Intergovernmental Negotiating Body responsible for negotiating the Pandemic Accord, attending the meetings, working with civil society partners to issue letters calling for greater participation and meeting with Member States. We also coordinated a series of FCDO/ DHSC meetings with civil society on the Pandemic Accord on behalf of Action for Global Health.

In January 2024, STOPAIDS began hosting the Civil Society Alliance (CSA) for Human Rights in the Pandemic Treaty (previously hosted by Harm Reduction International), providing financial and logistical support. This grant has enabled civil society colleagues to attend Pandemic Accord negotiations meetings and provided accessible information on the negotiation process. STOPAIDS continues as an active member of the Advisory Group, supporting the alliance’s advocacy to see key language on human rights in the negotiation text.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 19

MEMBERSHIP ENGAGEMENT

The aim of our membership engagement work is to ensure the growth and sustainability of our membership network and share knowledge and best practice to further our common goals. This includes ensuring diverse and relevant opportunities so that a broad range of members can engage and collaborate on activities to further our common goals and objectives.

Member meetings are a key opportunity for members to engage with the network on different thematic topics. A key meeting that we held in 2023 entitled ‘The HIV response: Influencing the Big Picture in the UK and globally’ was a great opportunity to convene our membership to discuss the current political landscape and big picture influencing opportunities. This meeting created an open space for us to discuss our collective ideas and messages to put forward to key influencing targets.

We also held a meeting in early 2024 entitled ‘Opportunities for engagement during the multilateral replenishments and general election.’ Ian Mitchell from the Center for Global Development provided an insightful presentation on the UK ODA context, while STOPAIDS staff presented on the multi-replenishment landscape, upcoming campaign plans, the Lusaka Agenda, and Global Public Investment.

In 2024-25 we plan to host a STOPAIDS members and partners meeting on how to push UK leadership in the global HIV response in the new year.

20 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

HOSTING AND SUPPORTING NETWORKS TO IMPROVE COLLABORATION AND COORDINATION

Our role in formally and informally supporting small organisations and groups is long established and is one of our five key strategic approaches to achieving our advocacy goals.

As a member-based convening network, STOPAIDS knows the value of support and facilitation, particularly for smaller organisations. Our contributions to global health and the HIV response are not just evidenced through our advocacy efforts but also our organisational structure.

STOPAIDS supports organisations/ groups in the global public health space to achieve their goals by hosting their staff and/or providing governance, financial administration, and project support services. This back-office support gives the institutional framework necessary for smaller organisations to exist and work without registering as separate legal entities- which is not always possible for smaller organisations from a capacity and resource standpoint.

In 2023-24 STOPAIDS hosted or supported:

• Action For Global Health

A UK advocacy network of four staff with 55 member organisations focused on global health. STOPAIDS holds AGH’s funding and employs its staff.

• Students For Global Health

A network of global health student campaigners in the UK. STOPAIDS holds SGH’s funding and employs its coordinator who is managed by the Action for Global Health.

• All Party Parliamentary Group (APPG) on HIV & AIDS

STOPAIDS employs the coordinator and provides the APPG with an annual grant.

• Youth STOPAIDS

A network of 300 youth campaigners. STOPAIDS financially supports and provides guidance to Youth STOPAIDS, and matrix manages the coordinator.

• UNITAID Board NGO Delegation

STOPAIES holds the delegation grant and employs the UNITAID NGO Delegation communication focal point.

• Global Network of People Living with HIV (GNP+)

STOPAIDS have an agreement with GNP+ to employ two GNP+ staff, based in the UK.

• UNITAID Board NGO Delegation STOPAIDS holds the delegation grant and employs the UNITAID NGO Delegation communications focal point.

• Civil Society Alliance for Human Rights in the Pandemic Treaty STOPAIDS provides financial and logistical support to the Alliance.

• Paediatric Adolescent Treatment Africa (PATA) STOPAIDS has an agreement with PATA on behalf of the Coalition for Children Affected to employ one staff member, based in the UK.

• Civil Society for Human Rights in the Pandemic Treaty STOPAIDS provides financial and logistical support and hosts the Co-ordinator’s consultancy

• Digital Health and Rights Project STOPAIDS is a member of the Digital Health and Rights Project Consortium.

• Inclusive Global Health Institutions Project STOPAIDS co-leads the Project with WACI Health, Global Fund Advocates Network (GFAN) and Global Network of People Living with HIV (GNP+).

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 21

LOOKING FORWARD: OUR PLANS FOR 2024/25

People over profit

• In 2024-25 we will focus on fundraising for our access to medicines work as this is an underfunded area. Funding is challenging across the missing medicines coalition, which is also affecting the capacity of other organisations and networks. We will focus the capacity we do have on advocacy around lenacapavir and what it means for the HIV response if we can overcome the barriers preventing people from accessing it.

• Over the next year the Digital Health and Rights Project, co-led by STOPAIDS, will undertake participatory action research with 300 young adults from marginalised communities in Kenya, Ghana, Vietnam and Kenya on digital rights. In parallel, STOPAIDS will lead the consortium’s advocacy efforts at the global level, to increase recognition and commitment for digital rights issues to be addressed by the WHO, the Global Fund and the UN Special Rapporteur on Racism, as well as in the latest and highest-level UN agreement on digital technologies - the ‘Global Digital Compact’.

Ensuring enhanced quality of life for people living with and affected by HIV

• In 2024-25 we will try to secure increased UK funding for key institutions in the global HIV response, through direct and collaborative advocacy for:

• the Robert Carr Network Fund which has its replenishment in August 2024,

• UNAIDS which seeks increased renewed funding

• The replenishment campaign of the Global Fund which will build over the year to October 2025

• The renewal of funding for Unitaid

• We will continue to engage with the Lusaka Agenda at global level and collaborate with african civil society colleagues to influence the African Lusaka Agenda Process

• We will engage in the International AIDS Conference in August 2024 across all pillars but particularly engaging in discussions on the future of HIV, HIV integration and LGBT rights

Transforming aid, solidarity and development co–operation

• In 2024-25 we will continue to champion the Principles of Meaningful Involvement of Communities and Civil Society in Global Health Governance and work with communities, civil society and global health institutions to ensure their implementation.

• We will continue to advocate for the meaningful involvement of communities and civil society in the negotiation of the Pandemic Accord and its future governance structure.

22 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

OUR STAFF

MIKE PODMORE Chief Executive Officer

SIOMHA CUNNIFFE

Director of Development and Engagement

SIMON BOWKETT

Director of Development and Engagement Maternity cover, January-October 2024

NICOLE WOODS

Finance Manager

OLIVIA COMPTON

Senior Communications and Community Engagement Advisor Left June 2024

VIVIENNE PRICE

Team Coordinator

SAOIRSE FITZPATRICK

Co-Director of Advocacy

TABITHA HA

Co-Director of Advocacy

JAMES COLE

Advocacy Manager Maternity cover, left August 2023

COURTENAY HOWE

Project Lead – Inclusive Global Health Institutions Project (WACI Health, GNP+, GFAN & STOPAIDS) / Advocacy Manager (STOPAIDS)

MOLLY PUGH JONES

Advocacy Manager

MOLLY THOMPSON

NGO Delegation Liaison Officer (UNITAID Board) / Senior Advocacy Advisor (STOPAIDS)

JAKE ATKINSON

Campaigns and Media Advisor Left September 2024

AMINA BABIRYE

Senior Advocacy Advisor

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 23

STRUCTURE, GOVERNANCE AND MANAGEMENT

Trustees

David Adams Frontline AIDS Appointed September 2024

Katherine Kirk Arie Results UK Appointed May 2023

Yael Azgad Avert

Tricia Cassidy mothers2mothers Chair from 12/9/2024

Colleen Daniels HRI Vice-Chair from 12/9/2024 Appointed May 2023

Romilly Greenhill ONE

Husseina Hamza Africa Advocacy Foundation

Vicki Howard Marie Stopes International Treasurer. Resigned August 2024

Rosemary Mburu WACI Health Appointed May 2023

Fionnuala Murphy Frontline AIDS Interim Chair. Resigned April 2024

Maria-Louise Rosbech Global Justice Now Appointed September 2024

Georgie Wallis Youth Stop AIDS Resigned September 2023

Principal officers

Michael Podmore Chief Executive Officer

Siomha Cunniffe Director of Development and Engagement

Registered office

167-169 Great Portland St, 5th Floor, London W1W 5PF, United Kingdom

Auditors

Wenn Townsend, 30 St Giles, Oxford OX1 3LE

Bankers

The Co-Operative Bank PO Box 101, 1 Balloon Street, Manchester M60 4EP

The directors of the charitable company are its trustees for the purpose of charity law and the members of the company limited by guarantee. Throughout this report they are collectively referred to as the Trustees or the Board of Trustees.

All trustees served for the full year unless otherwise indicated above. None had any beneficial interest in the charity and no remuneration of trustees/ directors is paid by the charity.

The trustees are pleased to present their report together with the audited financial statements of the charity for the year ended 31 March 2024.

Governing document

STOPAIDS is a charitable company limited by guarantee, incorporated on 6 March 1991 and registered as a charity on 19 March 2006, it changed its name from The UK Consortium on AIDS and International Development on 5th September 2013. The company was established under a Memorandum of Association which established the objectives and powers of the charitable company and is governed under its Articles of Association. These Articles were updated by members on 22nd January 2014.

24 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

Organisational structure

The Board of Trustees can have up to 12 members. It meets every three months and is responsible for the strategic direction, policy and overall governance of the charity. Members of the Board of Trustees, 10 members of which must be nominated from Member Organisations of STOPAIDS and two of which must be living with HIV, are elected to serve for a period of two years. They may stand for re-election once, serving for a maximum of four years, after which they must stand down for at least one year.

Once a Trustee has been elected to the Board, they meet with the Board Chair, the Director and the Development and Network Manager for an induction session. They are also introduced to the team and provided with an overview of each team member’s role. As part of the induction new Trustees are provided with a term of reference outlining the role, main responsibilities and tasks of the board and details about appointment and eligibility of board members, term of office, meetings and expectations of Trustees. Trustees are required to review and sign the Trustee Terms of Reference. They are also provided with the following documents: The Charity Commission’s Essential Trustee Guide, STOPAIDS’s governing documents, the most recent annual report and accounts, the organisational strategy, an organisational chart and an overview of the board sub-committees.

Trustees operate three sub-committees: Fundraising and Membership, Finance and HR. A minimum of 3 trustees sit on each sub-committee.

Day to day running and management, including financial management of STOPAIDS office and activities is the responsibility of the Secretariat, led by the Executive Director.

Key management personnel remuneration

The Trustees consider the Board of Trustees, the Director and the senior leadership team as comprising the key management personnel of the charity in charge of directing and controlling the charity and running and operating the charity on a day-to-day basis. All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses and related party transactions are disclosed in note 4 to the accounts.

Trustees are required to disclose all relevant interests and in accordance with the Trust’s policy withdraw from decisions where a conflict of interest arises.

The pay of the Director and senior leadership team is reviewed annually and is normally increased in line with our pay policy. The remuneration is reviewed to ensure that it is commensurate with similar roles.

Risk management

The Trustees review the risks the charity faces at every Trustee meeting. The Risk Log for the organisation continued to assess the low, medium, and high risks posed to the organisation and ensured discussion at the Board of priority actions to mitigate high risks. During the year risk management focused heavily on the Covid-19 pandemic- particularly its impact on STOPAIDS staff and member organisations, key at risk and marginalised populations within the UK and globally and the delivery of the STOPAIDS Strategic Plan. We also focused on cuts in funding and resource mobilisation for the HIV sector and the international development/ global public health sector due to the global cost of the pandemic. We also acknowledged that there has been a further shift in focus away from HIV by many generalist NGOs, as well as the UK Government.

STOPAIDS also works in close collaboration with Youth Stop AIDS and is committed to supporting the development of youth leadership in the global HIV response and therefore has one place on the Board for a representative of the Youth Stop AIDS network.

The Directors who held office during the year are listed under reference and administrative details above.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 25

Fundraising standards information

Members of the Charity’s fundraising department organise events and carry out fundraising activities to generate funds for the charity. The Charity does not use professional fundraisers or commercial participants. There have been no complaints about fundraising activity this year.

The charity has signed up to the Fundraising Regulator’s Code of Fundraising Practice.

All the charity’s marketing activities are undertaken directly to ensure that it is not unreasonably persistent or intrusive. Direct marketing materials contain clear details of how to unsubscribe to future communications and care is taken to limit the level of communications being sent out.

Objectives and activities

The relief of sickness, and the preservation and protection of good health of people living with HIV and AIDS or at risk of HIV transmission in developing countries by, in particular but not exclusively:

1. Providing a forum for the exchange of information among and between non-governmental bodies

2. Liaising with governmental and international bodies; and

3. Education of the public on hiv and aids and the work of non-governmental bodies in the field.

Public benefit statement

Trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing aims and objectives and planning future activities. Our direct beneficiaries of STOPAIDS are our member organisations and the organisations and groups that we host. However, the ultimate beneficiaries of all of our work are global population of people living with and affected by HIV and AIDS who are supported by our members and by the domestic and international STOPAIDS advocacy efforts and the technical support and advice we provide to the UK government and multilaterals on their role in the global HIV and broader global health inequity response.

Financial review

The Trustees are pleased with the financial performance this year, particularly considering the substantial economic challenges – including inflationary shocks – that occurred this year, including a cost-of-living crisis and inflation, and its impact to our funding streams. We have worked hard and continued strong relationships with funders and secured new sources of income whilst maintaining the backing and trust of our members, without whose financial and time contributions STOPAIDS would not thrive as a convening and advocating network.

STOPAIDS has continued to expand its role of hosting staff from other organisations working to similar objectives as STOPAIDS. This allows us to facilitate and support their work by managing employment contracts and back end financial and administrative office support at an overhead fee of 10-15% of the costs involved. As well as providing an essential service to other organisations without the capacity to function as separate legal entities, this allows economies of scale to further the efficiency of our operations.

Income for this period was £1,443,529 (£1,209,283 in 2022-23). This includes restricted funds from grant making trusts of £1,128,180 (compared to £996,080 in 2022-23). Monies from membership fees accounted for 8.3% of total income (10% the previous year).

Total expenditure for this period was £1,479,597 (£1,377,698 in 2022-23). Our income and expenditure increased this year due to a couple of factors; the securing of a few multi-year core grants, the expansion of the STOPAIDS team and the continued growth of Action for Global Health whom we host. There was a reduced deficit for the year of £36,068 (deficit of £168,415 in 2022-23), giving total funds of £444,261, of which £213,106 is unrestricted and £231,155 is restricted.

At the end of the year the charity remains in a healthy financial position and the trustees consider this to be a satisfactory result, particularly considering funding cuts experienced by many member organisations. It was a strong vote of support that members demonstrated their continued commitment to STOPAIDS through continued payment of membership fees. The charity will continue to closely review financial performance on a regular basis to ensure actual income and expenditure is in line with budget. There will be particular focus on income generation and diversifying sources of income to maintain this healthy position.

26 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

Reserves

It is the policy of STOPAIDS to maintain a reserves level to ensure delivery of core goals in line with the STOPAIDS Strategy. The trustees wish to ensure adequate reserves to mitigate any risks. Our general reserves fund policy is a minimum of 3 months running costs (£167,412) plus a portion of redundancy costs (£38,150) which is a total of £205K and up to 9 months operating costs (£502,236) plus a portion of redundancy costs (£38,150) which is a total of £540K. Our reserves policy does not include the running costs for hosted organisations; these funds are ringfenced in our restricted funds. Maintaining reserves at this level will ensure resilience against foreign exchange fluctuations, changes in membership funding and any other unanticipated impact of political changes and ensure that STOPAIDS can meet its legal obligations as an employer should be we cease to be a going concern/ experience a significant adverse event to our funding stream. The trustees review the policy against the Risk Register on a regular basis.

During the year our reserves, shown on the balance sheet as unrestricted funds have decreased to £209,777 (£251,932 in 2022-23), which are within the desired range as detailed above, however Trustees are working on a longer term goal of increasing reserves to a higher point in this range to further protect against risk.

Statement of trustees’ responsibilities

The Trustees (who are also directors of STOPAIDS the purposes of company law) are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year. In preparing these financial statements, the Trustees are required to:

• make judgements and estimates that are reasonable and prudent;

• state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

• prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

• there is no relevant audit information of which the charitable company’s auditor is unaware; and

• the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report has been prepared having taken advantage of the small companies’ exemption in the Companies Act 2006.

The accounts were approved at a meeting of the Trustees on 11th December 2024 and signed by:

Trustee: Chair, Patricia Cassidy

• select suitable accounting policies and then apply them consistently;

• observe the methods and principles in the Charities SORP 2019 (FRS 102);

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 27

Independent Auditor’s Report to the members of STOPAIDS

Opinion

We have audited the financial statements of STOPAIDS (the ‘charitable company’) for the year ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

• give a true and fair view of the state of the charitable company’s affairs as at 31 March 2024, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;

• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

• have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

28 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• the information given in the trustees’ report (incorporating the directors’ report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and

• the directors’ report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

• adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

• the financial statements are not in agreement with the accounting records and returns; or

• certain disclosures of directors’ remuneration specified by law are not made; or

• we have not received all the information and explanations we require for our audit; or

• the trustees were not entitled to prepare the financial statements in accordance with the small companies’ regime and take advantage of the small companies’ exemptions in preparing the directors’ report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on page 29, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

• Enquiry of management, those charged with governance and the entity’s solicitors around actual and potential litigation and claims;

• Reviewing minutes of meetings of those charged with governance;

• Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations;

• Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 29

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Benjamin Hayes BSc FCA

(Senior Statutory Auditor)

For and on behalf of Wenn Townsend Chartered Accountants and Statutory Auditor 30 St Giles Oxford OX1 3LE 11th December 2024

30 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

STOPAIDS

Statement of Financial Activities (including Income and Expenditure Account) for the year ended 31 March 2024

24,576 119,730 1,799 56,292 3,509	95,358 1,128,180 3,000 11,085 -	119,934 1,247,910 4,799 67,377 3,509	120,455 1,064,754 637 23,042 395
───────	───────	───────	───────
205,906	1,237,623	1,443,529	1,209,283
───────	───────	───────	───────
330	-	330	159
240,647	1,238,620	1,479,267	1,377,539
───────	───────	───────	───────
240,977	1,238,620	1,479,597	1,377,698
───────	───────	───────	───────
(35,071)	(997)	(36,068)	(168,415)
───────	───────	───────	───────
(3,755)	3,755	-	-
───────	───────	───────	───────
(38,826)	2,758	(36,068)	(168,415)
───────	───────	───────	───────
251,932	228,397	480,329	648,744
───────	───────	───────	───────
213,106	231,155	444,261	480,329
═══════	═══════	═══════	═══════

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 31

STOPAIDS Balance Sheet As at 31 March 2024

270,972 496,893	262,382 676,734
───────	───────
767,865	939,116
───────	───────
(326,933)	(461,287)
───────	───────
440,932	477,829
───────	───────
444,261	480,329
───────	───────
213,106	251,932
231,155	228,397
───────	───────
444,261	480,329
═══════	═══════

32 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

STOPAIDS

Statement of Cash Flows for the year ended 31 March 2024

(2,538)	(1,119)
───────	───────
(179,841)	(361,157)
676,734	1,037,891
───────	───────
496,893	676,734
═══════	═══════

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 33

Notes to the accounts for the year ended 31 March 2024

1. General information and basis of preparation

STOPAIDS is a charitable company limited by guarantee in England and Wales. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information in these financial statements. The nature of the charity’s operations and principal activities are detailed in the Trustees Report.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

2. (a) Basis of accounting

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

(b) Fund accounting

• (i) The unrestricted funds are available for use at the discretion of the trustees in furtherance of the objectives of the charity.

• (ii) Designated funds are unrestricted funds earmarked by the Executive Committee for particular purposes.

• (iii) Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal.

A final review of the allocation of expenditure is performed after a project or contract has been completed, which can give rise to a transfer between funds.

(c) Income

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

• (i) Income from grants, donations and gifts is included in full in the Statement of Financial Activities when receivable. Grants, where entitlement is not conditional on the delivery of a specific performance by the Charity, are recognised when the charity becomes unconditionally entitled to.

• (ii) Donated services and facilities are included at the value to the charity where this can be quantified.

• (iii) The value of services provided by volunteers has not been included in these accounts.

• (iv) Investment income arises from interest receivable on funds held in interest bearing bank accounts and is included when receivable.

• (v) Income from charitable trading activity is accounting for when earned.

(d) Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

• (i) Expenditure on raising funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes.

• (ii) Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

34 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

• (iii) Other expenditure included governance costs, those costs associated with meeting the constitutional and statutory requirements of the charity and include the independent examiner’s fees and costs linked to the strategic management of the charity and support costs.

• (iv) All costs are allocated between the expenditure categories of the SOFA on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, others are apportioned on an appropriate basis.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. The analysis of these costs is included in note 4.

(e) Fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life, which is typically applied at 33% per annum on the straight line method. Only items costing over £1,000 are capitalised.

(f) Foreign currency

Transactions in foreign currencies are initially recorded in the entity’s functional currency, which is pound sterling, by applying the spot exchange rate on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. All differences are taken to the Statement of Financial Activities.

(g) Debtors and creditors receivable / payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

(h) Impairment

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset’s cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

(i) Leases

Rentals payable and receivable under operating leases are charged to the SoFA on a straight line basis over the period of the lease.

(j) Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The charity operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

(k) Tax

The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.

(l) Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 35

3. (a) Income from grants and contracts

- - - - -	- - - 124,097 -	- - - 76,822 62,337	- - - - -	- - - 200,919 62,337	3,743 2,679 12,914 160,617 62,532
───────	───────	───────	───────	───────	───────
-	360,725	767,455	-	1,128,180	996,080
═══════	═══════	═══════	═══════	═══════	═══════
25,000	-	-	-	25,000	-
94,730	-	-	-	94,730	68,674
───────	───────	───────	───────	───────	───────
119,730	360,725	767,455	-	1,247,910	1,064,754
═══════	═══════	═══════	═══════	═══════	═══════

36 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

3. (b) Other income

19,577 - - 36,715 -	- - - 11,085 -	19,577 - - 47,800 -	10,632 6,437 2,683 2,750 540
───────	───────	───────	───────
56,292	11,085	67,377	23,042
═══════	═══════	═══════	═══════

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 37

4. Expenditure

(66,191)	66,191	-	-
───────	───────	───────	───────
230,218	1,238,620	1,468,838	1,365,888
───────	───────	───────	───────
251	-	251	306
5,700	-	5,700	6,600
4,478	-	4,478	4,745
───────	───────	───────	───────
10,429	-	10,429	11,651
───────	───────	───────	───────
240,647	1,238,620	1,479,267	1,377,539
═══════	═══════	═══════	═══════

5. Trustees’ renumeration and expenses

38 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

6. Staff costs and numbers

963,181 94,388 64,736	863,905 84,771 54,011
───────	───────
1,122,305	1,002,687
═══════	═══════
21	22
═════	═════

7. Fixed assets

27,757 2,538	27,757 2,538
─────	─────
30,295	30,295
─────	─────
25,257	25,257
1,709	1,709
─────	─────
26,966	26,966
─────	─────
3,329	3,329
─────	─────
2,500	2,500
─────	─────

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 39

8. Debtors: amounts falling due within one year

1. Creditors: amounts falling due within one year

----- Start of picture text -----
||| |---|---| |─────|─────| |123,710| |138,672| |─────|─────| |262,382| |═════|═════| |2024|2023| |£|£| |27,427|22,922| |395,409| |42,259|42,956| |─────|─────| |461,287| |═════|═════| |395,386| |(395,386)| |395,409| |─────|─────| |395,409| |═════|═════|

----- End of picture text -----

40 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

10. Movement in funds

24,601	200,919	-	(192,181)	33,339
───────	───────	───────	───────	───────
228,397	1,237,623	3,755	(1,238,620)	231,155
───────	───────	───────	───────	───────
251,932	205,906	(3,755)	(240,977)	213,106
───────	───────	───────	───────	───────
480,329	1,443,529	-	(1,479,597)	444,261
═══════	═══════	═══════	═══════	═══════

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 41

10. Movement in funds (continued)

1,465 9,993	- 160,617	(1,465) -	- (146,009)	- 24,601
───────	───────	───────	───────	───────
247,263	1,095,525	(4,683)	(1,109,708)	228,397
───────	───────	───────	───────	───────
401,481	113,758	4,683	(267,990)	251,932
───────	───────	───────	───────	───────
648,744	1,209,283	-	(1,377,698)	480,329
═══════	═══════	═══════	═══════	═══════

42 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

11. Analysis of net assets between funds

3,329 266,978 (57,201)	- 500,887 (269,732)	3,329 767,865 (326,933)
─────	─────	─────
213,106	231,155	444,261
═════	═════	═════
2,500	-	2,500
315,310	623,806	939,116
(65,878)	(395,409)	(461,287)
─────	─────	─────
251,932	228,397	480,329
═════	═════	═════

12. Reconciliation of net movement in funds to net cash flow from operating activities

(36,068) 1,709 (8,590) (134,354)	(168,415) 1,866 (182,350) (11,139)
─────	─────
(177,303)	(360,038)
═════	═════

13. Pension costs

14. Related party transactions

STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024 43

15. Comparative Statement of Financial Activities

───────	───────	───────
113,758	1,095,525	1,209,283
───────	───────	───────
159	-	159
267,831	1,109,708	1,377,539
───────	───────	───────
267,990	1,109,708	1,377,698
───────	───────	───────
(154,232)	(14,183)	(68,415)
───────	───────	───────
4,683	(4,683)	-
───────	───────	───────
(149,549)	(18,866)	(168,415)
───────	───────	───────
401,481	247,263	648,744
───────	───────	───────
251,932	228,397	480,329
═══════	═══════	═══════

44 STOPAIDS • ANNUAL REPORT AND ACCOUNTS APRIL 2023 – MARCH 2024

stopaids.org.uk [e-mail] f stopaidsuk x STOPAIDS 167-169 Great Portland Street, 5th Floor, London W1W 5PF Registered Charity No. 1113204 Company No. 2589198 All photos © STOPAIDS Design and layout: causeffectdesign.co.uk